Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

66.92 +0.11 (+0.16%)
Official Closing Price Updated: 7:00 PM EDT, Sep 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,933,600
Open 67.58
Bid (Size) 66.10 (200)
Ask (Size) 67.15 (1,100)
Prev. Close 66.81
Today's Range 66.64 - 68.04
52wk Range 42.52 - 68.64
Shares Outstanding 2,222,113,553
Dividend Yield 3.77%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Branded Pharmaceuticals Stocks Q2 Teardown: Bristol-Myers Squibb (NYSE:BMY) Vs The Rest
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Reasons to Sell BMY and 1 Stock to Buy Instead
Even though Bristol-Myers Squibb (currently trading at $66.44 per share) has gained 6.6% over the last six months, it has lagged the S&P 500’s 12.3% return d... 
Via StockStory
Topics Stocks

Performance

YTD
+25.2%
+25.2%
1 Month
+2.2%
+2.2%
3 Month
+22.9%
+22.9%
6 Month
+9.3%
+9.3%
1 Year
+41.2%
+41.2%

More News

Read More
News headline image
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
1 S&P 500 Stock with Promising Prospects and 2 Facing Challenges
Via StockStory
Topics Stocks
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
Via FinancialNewsMedia
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
3 Dividend Stocks to Hold for the Next 10 Years ↗
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset? ↗
Via The Motley Fool
Topics ETFs
News headline image
Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Corcept (NASDAQ:CORT)
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now ↗
Via The Motley Fool
News headline image
1 Momentum Stock on Our Buy List and 2 We Turn Down
Via StockStory
News headline image
Are Mega-Mergers Back? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen? ↗
Via The Motley Fool
News headline image
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
From Bristol Myers Squibb
Via Business Wire
News headline image
Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent Clock ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas
From Bristol Myers Squibb
Via Business Wire
News headline image
1 Profitable Stock with Impressive Fundamentals and 2 We Avoid
Via StockStory
News headline image
Bristol-Myers Squibb’s Q2 Earnings Call: Our Top 5 Analyst Questions
Via StockStory
Topics Earnings
News headline image
Bristol-Myers Squibb (BMY) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
Which S&P500 stocks are moving before the opening bell on Monday? ↗
Via Chartmill
News headline image
Bristol Myers Squibb Isn't Nearly as Cheap as It Looks -- Here's the 1 Thing That Could Change That ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol Myers Squibb Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 66.92
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 09/01/26 07:00 PM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 148.70B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 149B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.